We are live on ! Find out more
MRTX

Mirati Therapeutics, Inc. Common Stock
MRTX

Delisted

MRTX was delisted on the 22nd of January, 2024.

Back to rankings

63 hedge funds and large institutions have $408M invested in Mirati Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

528% more call options, than puts

Call options by funds: $2.3M | Put options by funds: $366K

200% more funds holding in top 10

Funds holding in top 10: 2 → 6 (+4)

108% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 13

100% more capital invested

Capital invested by funds: $204M → $408M (+$204M)

67% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 12

29% more funds holding

Funds holding: 49 → 63 (+14)

Holders
63
Holders Change
+14
Holders Change %
+28.57%
% of All Funds
1.43%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.14%
New
27
Increased
20
Reduced
12
Closed
13
Calls
$2.3M
Puts
$366K
Net Calls
+$1.93M
Net Calls Change
+$340K

Top Buyers

Rank Fund Capital Flow
1
PI
Putnam Investments
Massachusetts
+$14.6M
2
ACA
Avoro Capital Advisors
New York
+$10.7M
3
State Street
State Street
Massachusetts
+$10.6M
4
GTC
Ghost Tree Capital
New York
+$9.31M
5
Jennison Associates
Jennison Associates
New York
+$7.57M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$5.21M
2
Morgan Stanley
Morgan Stanley
New York
-$2.33M
3
RA
Royce & Associates
New York
-$2.02M
4
MWNA
Marshall Wace North America
New York
-$1.93M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
SG Americas Securities
26
SG Americas Securities
New York
$829K +$705K +45,430 New
Citigroup
27
Citigroup
New York
$758K +$644K +41,524 New
OAM
28
Oxford Asset Management
United Kingdom
$642K +$29.5K +1,900 +6%
EI
29
EAM Investors
California
$635K +$540K +34,818 New
Goldman Sachs
30
Goldman Sachs
New York
$591K +$503K +32,408 New
SSA
31
Schonfeld Strategic Advisors
New York
$586K +$498K +32,113 New
Citadel Advisors
32
Citadel Advisors
Florida
$548K +$112K +7,193 +31%
PA
33
Perceptive Advisors
New York
$531K +$451K +29,091 New
Jacobs Levy Equity Management
34
Jacobs Levy Equity Management
New Jersey
$520K +$77.6K +5,000 +21%
PP
35
PDT Partners
New York
$460K -$667K -42,976 -63%
UBS Group
36
UBS Group
Switzerland
$460K +$165K +10,620 +73%
Lazard Asset Management
37
Lazard Asset Management
New York
$371K +$316K +20,383 New
VEA
38
Virtus ETF Advisers
New York
$361K +$307K +19,786 New
VFA
39
Virtus Fund Advisers
Connecticut
$361K +$307K +19,786 New
Ameriprise
40
Ameriprise
Minnesota
$341K +$290K +18,678 New
AGM
41
Alpine Global Management
New York
$337K +$287K +18,472 New
Barclays
42
Barclays
United Kingdom
$328K +$85.3K +5,500 +44%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$323K +$27.3K +1,761 +11%
Morgan Stanley
44
Morgan Stanley
New York
$290K -$2.33M -150,235 -90%
KM
45
Kalos Management
Georgia
$232K +$776 +50 +0.4%
MWNA
46
Marshall Wace North America
New York
$229K -$1.93M -124,398 -91%
Balyasny Asset Management
47
Balyasny Asset Management
Illinois
$224K -$144K -9,300 -43%
RJFSA
48
Raymond James Financial Services Advisors
Florida
$207K +$176K +11,326 New
Federated Hermes
49
Federated Hermes
Pennsylvania
$193K -$140K -9,001 -46%
Deutsche Bank
50
Deutsche Bank
Germany
$30K -$231K -14,888 -90%
1
2
3 4

MRTX Hedge Fund Activity: Q4 2017 in Review

63 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q4 2017, worth a combined $408M — up 100% from $204M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new MRTX positions and 13 closed out — a net gain of 14 holders — while 20 added to existing stakes and 12 trimmed.

The largest buyer was Putnam Investments, opening a new position worth an estimated $14.6M. The largest seller was Millennium Management, exiting entirely with an estimated $5.21M sold.

  • 63 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q4 2017, up from 49 in Q3 2017.
  • Funds reported $408M of Mirati Therapeutics, Inc. Common Stock stock for Q4 2017, up 100% quarter-over-quarter.
  • 27 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q4 2017 and 13 closed out, a net change of +14 holders.
  • The largest Mirati Therapeutics, Inc. Common Stock buyer in Q4 2017 was Putnam Investments, an estimated $14.6M added.
  • The largest Mirati Therapeutics, Inc. Common Stock seller in Q4 2017 was Millennium Management, an estimated $5.21M sold.

Based on aggregated 13F filings for Q4 2017.